US Embassy Slams Dutch Compounding Policy
The US embassy in the Netherlands has attacked Dutch policies on compounding and compulsory licensing. Critics have accused it of scaremongering.
You may also be interested in...
While the Dutch government negotiates an acceptable price for Leadiant Biosciences’ orphan drug CDCA, a university hospital has resumed supplying pharmacy compounded versions of the drug after addressing initial problems with the sourcing of raw materials.
The Netherlands will secure lower medicine prices by referencing Norway instead of Germany to set maximum prices.
Compulsory licensing, new R&D models, and pharmaceutical compounding are among measures that could help secure lower drugs prices, according to a report from the Dutch Council for Public Health and Society.